---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-23-000258"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:31:41.971829+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Enochian BioSciences receives Nasdaq notice for delayed Form 10-Q filing and amends convertible notes

## Summary
- Amended and restated two $600,000 convertible notes with Paseco ApS, extending maturity to February 28, 2024 and securing obligations.
- Amended a $5,000,000 promissory note from March 2020 to secure obligations under a new security agreement.
- Entered into a security agreement granting Paseco ApS a first priority security interest in all of Enochian's assets.
- Received Nasdaq notice on February 16, 2023 for non-compliance due to delayed filing of Form 10-Q for period ended December 31, 2022.
- Nasdaq previously accepted compliance plan; deadline to regain compliance is April 11, 2023.

## SEC filing metadata
- accession: 0001731122-23-000258
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/e4441_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-23-000258
- JSON: https://secwatch.observer/filing/0001731122-23-000258.json
- Plain text: https://secwatch.observer/filing/0001731122-23-000258.txt

## Key facts
- Listing & Compliance Notices
  Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: February 16, 2023, the Company received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “ Form 10-Q ”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Co
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm
- Material Agreements
  Lunai Bioworks Inc. amended Amended and Restated February Notes with Paseco ApS valued at $600,000 (effective 2022-12-30).
  - Action: amendment
  - Counterparty: Paseco ApS
  - Value: $600,000
  - Effective: 2022-12-30
  source text: On February 16, 2023, the Company amended and restated those two certain convertible promissory notes between the Company and Paseco ApS (the “ Holder ”) dated February 6, 2020, each in the principal amount of $600,000 (the “ February Notes ”) by entering into two amended and restated secured convertible promissory notes, each with an effective date of December 30, 2022 and each in the principal amount of $600,000 (the “ Amended and Restated February Notes ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm
- Material Agreements
  Lunai Bioworks Inc. amended Amendment to the March Note with Paseco ApS valued at $5,000,000 (effective 2022-12-30).
  - Action: amendment
  - Counterparty: Paseco ApS
  - Value: $5,000,000
  - Effective: 2022-12-30
  source text: On February 16, 2023, the Company amended that certain promissory note dated March 30, 2020 in the principal amount of $5,000,000 between the Company and the Holder (the “ March Note ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm
- Material Agreements
  Lunai Bioworks Inc. entered into Security Agreement with Paseco ApS (effective 2022-12-30).
  - Action: entry
  - Counterparty: Paseco ApS
  - Effective: 2022-12-30
  source text: On February 16, 2023, the Company entered into a security agreement between the Company and the Holder, effective as of December 30, 2022 (the “ Security Agreement ”) under which the Company pledged and granted the Holder a first priority security interest in and lien upon all of the Company’s wholly-owned assets as collateral security for the prompt payment in full of the principal amounts of the February Notes and the March Note when due.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/0001731122-23-000258-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.